OS Therapies Inc. (NYSE American: OSTX)

OS Therapies Inc.
15825 Shady Grove Rd.
Rockville, MD 20850
Phone: (410) 849-9067
https://ostherapies.com/ 

OS Therapies Inc. (“OS Therapies” or “the Company”) is a clinical-stage cancer immunotherapy company focused on discovering, developing, and commercializing treatments for osteosarcoma and other solid tumors. The Company has built a diversified pipeline around two novel technology platforms: OST-Lm, a bioengineered form of Listeria monocytogenes designed to drive robust immune responses against HER2-expressing cancer cells; and OST-tADC, a next-generation tunable antibody-drug conjugate platform. The lead OST-Lm program, OST-HER2, is in clinical development for osteosarcoma and breast cancer and holds conditional approval for canine osteosarcoma. A Phase 2b clinical trial in resected lung-metastatic osteosarcoma has completed its treatment phase and has demonstrated statistically significant improvements in 12-month Event-Free Survival (EFS) (primary endpoint) and overall survival (OS) (secondary endpoint), with a favorable safety profile. OS Therapies’ pipeline also includes multiple mid- and early-stage assets—OST-AXAL (HPV-related cancers), OST-503 (NSCLC and glioblastoma), and OST-504/PSA (prostate cancer)—along with additional preclinical programs targeting more than 30 solid tumor types. OS Therapies is also advancing its proprietary OST-tADC platform, currently in pre-clinical development. The Company is initially assessing the use of this platform on ovarian and breast cancer. The Company established a subsidiary, OS Drug Conjugates, to develop the OST-tADC platform internally and pursue licensing and partnership opportunities.

* Updated on January 9, 2026.

*******************************************

Listen to our podcast:

 Inside_OS_Therapies_Immunotherapy_Data_and_the_Road_to_Filing

*******************************************